2020

Development of a targeted and controlled nanoparticle delivery system for FoxO1 inhibitors

Andrea Ferrer Vega  
*Virginia Commonwealth University*

Michael Imondo

Andriy Mulyar

*See next page for additional authors*

Follow this and additional works at: [https://scholarscompass.vcu.edu/gradposters](https://scholarscompass.vcu.edu/gradposters)

Part of the *Social and Behavioral Sciences Commons*

**Downloaded from**  
Ferrer Vega, Andrea; Imondo, Michael; Mulyar, Andriy; McInnes, Bridget T.; Cheng, Zhiyong; and Lewinski, Nastassja, "Development of a targeted and controlled nanoparticle delivery system for FoxO1 inhibitors" (2020). *Graduate Research Posters*. Poster 69.  
[https://scholarscompass.vcu.edu/gradposters/69](https://scholarscompass.vcu.edu/gradposters/69)

This Poster is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Graduate Research Posters by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Authors
Andrea Ferrer Vega, Michael Imondo, Andriy Mulyar, Bridget T. McInnes, Zhiyong Cheng, and Nastassja Lewinski

This poster is available at VCU Scholars Compass: https://scholarscompass.vcu.edu/gradposters/69
Development of a targeted and controlled nanoparticle delivery system for FoxO1 inhibitors

Andrea Ferrer Vega¹, Michael Imono¹, Andriy Mulyar², Bridget T. McInnes², Zhiyong Cheng³, Nastassja Lewinski¹

¹Virginia Commonwealth University, Chemical and Life Science Engineering, ²Virginia Commonwealth University, Computer Science, ³University of Florida, Food Science and Human Nutrition

Abstract

Poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) are polymers approved by the United States’ Food and Drug Administration due to their biocompatibility with humans. Drugs for various medical treatments have been encapsulated in PLGA-PEG nanoparticles for targeted delivery and reducing unwanted side effects. In this research, a flow synthesis method for PLGA-PEG nanoparticles with FoxO1 inhibitors and adipose vasculature targeting agent were studied. These drugs inhibit the FoxO1 pathway targeting white adipose tissues and converting them from an energy storing state to an energy burning state. A set of nanoparticles were characterized by Dynamic Light Scattering, Fluorescence Spectroscopy, Transmission Electron Microscopy and Dialysis to measure hydrodynamic diameter, size distribution, zeta potential, stability, yield and encapsulation efficiency.

Introduction

Figure 1. Schematic of the browning of white adipose tissue.¹

Figure 2. Representation of PLGA-PEG-P3-AS1842856 nanoparticle.

• Around one third of the United States population is obese.
• The medical approach to treating this disorder is mainly focused on diet and exercise.
• Inhibition of the FoxO1 pathway allows for browning of adipose tissue to occur.
• Poly(lactic-co-glycolic acid) and polyethylene glycol are polymers used in the synthesis of nanoparticles for targeted drug delivery.
• Flow chemistry allows for more uniform particle formation as well as repeatability across batches.
• Our synthesis approach was compared to over 270 research articles using information extraction tools.

Experimental Design

Synthesis

PLGA unloaded
PLGA-PEG-P3 unloaded
PLGA-PEG-P3 loaded

Characterization

Dynamic Light Scattering
Fluorescence Spectroscopy
TEM
Dialysis
Endotoxin Levels

Results

Figure 4. TEM image of PLGA nanoparticles.

Figure 5. Size of PLGA nanoparticles.

• PLGA-PEG-P3-AS1842856 nanoparticles had a range of sizes from 142.4 ± 0.4 d.nm to 208.7 ± 3.5 d.nm. This was confirmed with TEM imaging.
• The polydispersity index was less than 0.500 for all the samples, ranging from 0.057 ± 0.021 to 0.369 ± 0.038.
• Zeta potential values for the nanoparticles synthesized ranged from -4.330 mV ± 0.214 mV to 1.89mV.
• Stability testing indicated that the nanoparticles are stable for at least a month after production, based on particle size measurements.
• When comparing both PLGA and PLGA-AS1842856 nanoparticles it was evident that the drug is being encapsulated due to the change in size and fluorescence intensity. This was also the case with PLGA-PEG-P3 samples.
• Through fluorescence spectroscopy, the encapsulation efficiency was determined to be 100% for both AS1842856 drug loaded nanoparticles synthesized.
• Elevated endotoxin levels were measured in the synthesized particle suspensions.
• No nanoprecipitation occurred when using the same synthesis approach for two other hydrophilic drugs.

Future Work

• Control the release profile of the drug loaded nanoparticles in vitro.
• Develop PLGA-PEG loaded and unloaded nanoparticles for comparison.
• Determination of peptide conjugation efficiency.
• Carry out in vivo models with the developed nanoparticles.
• Manage the endotoxin levels in the nanoparticles.
• Study alternative syntheses such as water/oil/water emulsion or liposomal encapsulation for the other more hydrophilic drugs.

References


Acknowledgements

I would like to acknowledge:
• Dr. Nastassja Lewinski and my fellow lab mates for their continued support through the development of this research.
• Judy Williamson and the VCU Microscopy Core for assistance with TEM images.
• The American Heart Association and Jeffress Trust for their financial support of this research.